Improved Calcitonin-based Therapeutics

Invention The aggregation site on human calcitonin has been identified, paving the way for development of specific inhibitors of calcitonin amyloid fibril formation. Such inhibitors will enable development of improved calcitonin therapeutics as well as greatly facilitate in vitro calcitonin manipulations.
The Need The therapeutic use of human calcitonin is severely limited by its tendency to associate and form fibrils. Salmon calcitonin, which is used in the clinic, causes immunogenic reactions in some treated patients owing to low sequence homology compared to the human form. There is thus a clear need for a calcitonin based therapeutic which is non-immunogenic and does not associate to form fibrils.
Potential Applications
· Calcitonin therapy

o Osteoporosis therapy

o Paget's disease

· In vitro calcitonin solubilizer
Advantages
· Short peptides

· Cheap & simple to produce
Stage Short peptide inhibitors of human calcitonin aggregation have been synthesized characterized and tested in vitro.
References Reches M, Porat Y, Gazit E. 2002 Amyloid fibril formation by pentapeptide and tetrapeptide fragments of human calcitonin. J Biol Chem. 277: 35475-35480
Patent Pending Tech Transfer Officer Dr. Nissim Chen Office: +972-3-6406121 Fax: +972-3-6406675 Mail: [email protected]

Inventor(s): Ehud Gazit

Type of Offer: Licensing



Next Patent »
« More Pharmaceutical Patents

Share on      


CrowdSell Your Patent